Alzheimer Trial Design And Atypical Variants

As disease-modifying therapies for Alzheimer's disease (AD) become increasingly available, researchers are calling attention to a group of patients who have historically been overlooked in clinical trials: those with atypical variants of the disease.

A new perspective argues that atypical Alzheimer's disease presents a unique opportunity to improve the design of future clinical trials while addressing longstanding gaps in treatment evidence. Although these variants share the core biological features of Alzheimer's disease, they often present with non-amnestic symptoms, occur at younger ages, and follow a more aggressive clinical course than the typical memory-predominant form of the disease.

Unlike the gradual memory loss that characterizes typical Alzheimer's disease, atypical variants encompass a range of clinical syndromes affecting language, executive function, visuospatial abilities, behavior, or motor function. These include dysexecutive Alzheimer's disease, logopenic variant primary progressive aphasia, posterior cortical atrophy, behavioral variant Alzheimer's disease, and corticobasal syndrome due to Alzheimer's disease. Although these presentations are more common among people with early-onset Alzheimer's disease, they are distinct clinical entities and can occur across the age spectrum.

The authors note that patients with atypical Alzheimer's disease frequently experience delayed or incorrect diagnoses because their symptoms and younger age at onset often lead clinicians to consider psychiatric disorders, sensory conditions, or other non-neurodegenerative causes. As a result, many patients have more advanced disease by the time Alzheimer's disease is recognized, limiting opportunities for early intervention and enrollment in clinical research.

Despite these challenges, most large Phase III clinical trials evaluating disease-modifying therapies have focused almost exclusively on older adults with memory-predominant Alzheimer's disease. Recent trials of anti-amyloid monoclonal antibodies, including lecanemab and donanemab, primarily enrolled participants with mild cognitive impairment or mild dementia characterized by episodic memory impairment. While current treatment recommendations allow use of these therapies in atypical Alzheimer's disease, evidence supporting their effectiveness in non-amnestic presentations remains limited because these populations were largely underrepresented or excluded from pivotal studies.

The perspective suggests that atypical Alzheimer's disease may, in fact, represent an ideal model for clinical trials. Compared with late-onset amnestic Alzheimer's disease, atypical variants often decline more rapidly, potentially allowing treatment effects to become apparent over conventional trial timelines. In addition, these patients may more directly reflect Alzheimer's disease pathology because they are less frequently affected by age-related co-pathologies such as cerebrovascular disease or TDP-43 proteinopathy. The authors emphasize, however, that any suggestion of differential treatment response remains hypothetical and requires dedicated clinical investigation.

Designing trials for atypical Alzheimer's disease presents unique challenges. Current outcome measures frequently emphasize memory performance and may not adequately capture changes in language, visuospatial processing, executive function, behavior, or motor symptoms that define atypical syndromes. Likewise, neuroimaging approaches developed for typical Alzheimer's disease may underestimate disease burden because patterns of tau deposition differ substantially across atypical variants.

These considerations raise important questions about whether atypical Alzheimer's disease should be incorporated into broader Alzheimer's trials using expanded outcome measures or studied through dedicated phenotype-specific clinical trials. To address these issues, the authors recommend broadening participant eligibility by lowering age thresholds and enrolling biomarker-confirmed Alzheimer's disease regardless of clinical phenotype. They also advocate for the development of trial-ready observational cohorts, harmonized diagnostic criteria, syndrome-specific cognitive assessments, and biological outcome measures that better reflect the diversity of atypical Alzheimer's disease. Existing initiatives, including the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), are highlighted as potential platforms for supporting future interventional research.

The perspective also outlines several clinical trial designs that could improve representation of atypical Alzheimer's disease. Depending on the therapeutic target and study objectives, investigators could incorporate atypical participants into conventional Alzheimer's disease trials, develop phenotype-specific studies, or pursue basket, platform, or multi-arm trial designs that allow multiple clinical phenotypes to be evaluated within a shared biological framework. The authors note that the choice of design should balance biological precision, clinical heterogeneity, feasibility, and statistical power.

Beyond trial methodology, the authors argue that improving research participation will require broader efforts to increase awareness of atypical Alzheimer's disease among clinicians, expand access to biomarker testing and advanced neuroimaging, establish collaborative research networks, engage patients and caregivers in study development, and support regulatory and funding frameworks that encourage research in these underrepresented populations.

The authors conclude that expanding therapeutic research to encompass atypical Alzheimer's disease is both a scientific opportunity and an ethical imperative. They propose that adapting clinical trial infrastructure to better reflect the full phenotypic spectrum of Alzheimer's disease could improve diagnostic accuracy, broaden access to emerging therapies, and generate evidence that is more representative of the diverse populations affected by the disease.